CL2018003821A1 - Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo. - Google Patents
Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo.Info
- Publication number
- CL2018003821A1 CL2018003821A1 CL2018003821A CL2018003821A CL2018003821A1 CL 2018003821 A1 CL2018003821 A1 CL 2018003821A1 CL 2018003821 A CL2018003821 A CL 2018003821A CL 2018003821 A CL2018003821 A CL 2018003821A CL 2018003821 A1 CL2018003821 A1 CL 2018003821A1
- Authority
- CL
- Chile
- Prior art keywords
- triazolo
- pyridinyl
- compounds
- compounds substituted
- indole compounds
- Prior art date
Links
- -1 (1,2,4) triazolo (1,5-a) pyridinyl Chemical group 0.000 title 1
- 125000001041 indolyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101100099924 Drosophila melanogaster Toll-7 gene Proteins 0.000 abstract 1
- 101100099925 Drosophila melanogaster Tollo gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA (1) O UNA SAL DEL MISMO, EN DONDE R1, R2, R3, R4, R5, M, N Y P SE DEFINEN EN LA PRESENTE. TAMBIÉN SE DESCRIBEN MÉTODOS PARA USAR TALES COMPUESTOS COMO INHIBIDORES DE LA SEÑALIZACIÓN A TRAVÉS DEL RECEPTOR TIPO TOLL 7, 8 O 9, Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS. ESTOS COMPUESTOS SON ÚTILES PARA TRATAR ENFERMEDADES INFLAMATORIAS Y AUTOINMUNITARIAS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611022328 | 2016-06-29 | ||
| US15/635,055 US10071079B2 (en) | 2016-06-29 | 2017-06-27 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003821A1 true CL2018003821A1 (es) | 2019-04-22 |
Family
ID=60805851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003821A CL2018003821A1 (es) | 2016-06-29 | 2018-12-27 | Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo. |
Country Status (30)
| Country | Link |
|---|---|
| US (8) | US10071079B2 (es) |
| EP (1) | EP3478682B1 (es) |
| JP (1) | JP6995067B6 (es) |
| KR (1) | KR102473482B1 (es) |
| CN (1) | CN109641895B (es) |
| AR (1) | AR108905A1 (es) |
| AU (1) | AU2017287902B2 (es) |
| CL (1) | CL2018003821A1 (es) |
| CO (1) | CO2019000686A2 (es) |
| CY (1) | CY1124514T1 (es) |
| DK (1) | DK3478682T3 (es) |
| EA (1) | EA037530B1 (es) |
| ES (1) | ES2886964T3 (es) |
| HR (1) | HRP20211261T8 (es) |
| HU (1) | HUE056091T2 (es) |
| IL (1) | IL263961B (es) |
| LT (1) | LT3478682T (es) |
| MX (1) | MX376212B (es) |
| MY (1) | MY196474A (es) |
| PE (1) | PE20190324A1 (es) |
| PL (1) | PL3478682T3 (es) |
| PT (1) | PT3478682T (es) |
| RS (1) | RS62292B1 (es) |
| SG (1) | SG11201811590RA (es) |
| SI (1) | SI3478682T1 (es) |
| SM (1) | SMT202100513T1 (es) |
| TW (1) | TWI636053B (es) |
| UY (1) | UY37310A (es) |
| WO (1) | WO2018005586A1 (es) |
| ZA (1) | ZA201900571B (es) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| AU2017307208B2 (en) | 2016-07-30 | 2021-01-21 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
| JP7028861B2 (ja) | 2016-09-09 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | ピリジル置換のインドール化合物 |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| EP3661934B1 (en) * | 2017-08-04 | 2022-06-01 | Bristol-Myers Squibb Company | [1,2,4]triazolo[4,3-a]pyridinyl substituted indole compounds |
| JP7104775B2 (ja) | 2017-08-04 | 2022-07-21 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物 |
| EP3710440B1 (en) | 2017-11-14 | 2023-04-05 | Bristol-Myers Squibb Company | Substituted indole compounds |
| SG11202005513TA (en) | 2017-12-15 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole ether compounds |
| AU2018392316B2 (en) | 2017-12-19 | 2022-05-12 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as TLR inhibitors |
| AU2018390820A1 (en) * | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | Substituted indole compounds useful as TLR inhibitors |
| CN111699185B (zh) | 2017-12-19 | 2023-06-27 | 百时美施贵宝公司 | 6-氮杂吲哚化合物 |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| JP7291707B2 (ja) | 2017-12-20 | 2023-06-15 | ブリストル－マイヤーズ スクイブ カンパニー | アリールおよびヘテロアリール置換されたインドール化合物 |
| KR102492115B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드 |
| JP7382938B2 (ja) * | 2017-12-20 | 2023-11-17 | ブリストル－マイヤーズ スクイブ カンパニー | ジアザインドール化合物 |
| KR102714788B1 (ko) * | 2017-12-20 | 2024-10-08 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr 억제제로서 유용한 아미노 인돌 화합물 |
| CN111699187A (zh) | 2018-02-12 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的砜化合物和衍生物 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| KR20210018818A (ko) | 2018-06-05 | 2021-02-18 | 에프. 호프만-라 로슈 아게 | 자가면역 질환의 치료를 위한 테트라하이드로-1H-피라지노[2,1-a]이소인돌릴퀴놀린 화합물 |
| JP7434186B2 (ja) | 2018-06-12 | 2024-02-20 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規のヘテロアリールヘテロシクリル化合物 |
| WO2019238629A1 (en) * | 2018-06-13 | 2019-12-19 | F. Hoffmann-La Roche Ag | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease |
| WO2020020800A1 (en) | 2018-07-23 | 2020-01-30 | F. Hoffmann-La Roche Ag | Novel piperazine compounds for the treatment of autoimmune disease |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| EP3847169A1 (en) | 2018-09-04 | 2021-07-14 | F. Hoffmann-La Roche AG | Benzothiazole compounds for the treatment of autoimmune diseases |
| JP2022502353A (ja) | 2018-09-06 | 2022-01-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の処置のための新規の環状アミジン化合物 |
| CN112654620B (zh) | 2018-09-06 | 2023-08-04 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型吡唑并吡啶化合物 |
| JP7597710B2 (ja) * | 2018-10-24 | 2024-12-10 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドール二量体の化合物 |
| WO2020086503A1 (en) * | 2018-10-24 | 2020-04-30 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
| AU2019372046B2 (en) | 2018-10-31 | 2022-05-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ３’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3966212A1 (en) * | 2019-05-07 | 2022-03-16 | Bristol-Myers Squibb Company | Prodrug compounds |
| ES2987832T3 (es) * | 2019-05-09 | 2024-11-18 | Bristol Myers Squibb Co | Compuestos de benzimidazolona sustituidos |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN110146631B (zh) * | 2019-06-25 | 2021-11-12 | 山西康宝生物制品股份有限公司 | 一种药用材料中聚乙二醇单甲醚残留量的检测方法 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| WO2021067326A1 (en) | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| US12384760B2 (en) | 2019-10-04 | 2025-08-12 | Bristol-Myers Squibb Company | Substituted carbazole compounds |
| US12421240B2 (en) | 2019-10-31 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| EP4061816A1 (en) | 2019-11-19 | 2022-09-28 | F. Hoffmann-La Roche AG | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| JP7649306B2 (ja) | 2019-11-20 | 2025-03-19 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのスピロ（イソベンゾフラナゼチジン）化合物 |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| JP7751597B2 (ja) * | 2020-06-11 | 2025-10-08 | ブリストル－マイヤーズ スクイブ カンパニー | 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤 |
| AU2021296150A1 (en) | 2020-06-22 | 2023-02-23 | Bristol-Myers Squibb Company | Treating rheumatoid arthritis |
| WO2022022489A1 (zh) * | 2020-07-27 | 2022-02-03 | 江苏恒瑞医药股份有限公司 | 吲哚稠环类衍生物、其制备方法及其在医药上的应用 |
| BR112023002737A2 (pt) | 2020-08-19 | 2023-03-14 | Bristol Myers Squibb Co | Derivados de imidazo[1,2-a]piridina e [1,2,4]triazolo[1,5-a]piridina como inibidores de tlr9 para o tratamento de fibrose |
| US12492188B2 (en) | 2020-08-19 | 2025-12-09 | Bristol-Myers Squibb Company | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis |
| JP2023550793A (ja) | 2020-11-26 | 2023-12-05 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 縮合三環式化合物、その調製方法及びその医薬的応用 |
| CN116783202A (zh) * | 2021-02-09 | 2023-09-19 | 吉利德科学公司 | 噻吩并吡咯化合物 |
| PE20240919A1 (es) | 2021-04-16 | 2024-04-30 | Gilead Sciences Inc | Compuestos de tienopirrol |
| JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ |
| CN113416188B (zh) * | 2021-05-31 | 2022-12-13 | 河南偶联生物科技有限公司 | 一种[1,2,4]三唑并[1,5-a]吡啶化合物的合成方法 |
| CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| KR20240056747A (ko) | 2021-09-10 | 2024-04-30 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| EP4554932A1 (en) | 2022-07-13 | 2025-05-21 | Bristol-Myers Squibb Company | Processes for preparing 5-bromo-3,4-dimethylpyridin-2-amine and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine |
| WO2025075944A1 (en) | 2023-10-02 | 2025-04-10 | Bristol-Myers Squibb Company | A method of treating lupus |
| WO2025106385A1 (en) | 2023-11-13 | 2025-05-22 | Bristol-Myers Squibb Company | 2-(4-(2-(7,8-dimethyl-[l,2,4jtriazolo[l,5-a]pyridin-6-yl)-3-isopropyl- lh-indol-5-yl)piperid!n-l-yl)acetamide and crystalline forms thereof |
| TW202527943A (zh) | 2023-11-13 | 2025-07-16 | 美商必治妥美雅史谷比公司 | 2-(4-(2-(7,8-二甲基-[1,2,4]三唑[1,5-a]吡啶-6-基)-3-異丙基-1h-吲哚-5-基)哌啶-1-基)乙醯胺鹽及其結晶形式 |
| WO2025137344A1 (en) | 2023-12-20 | 2025-06-26 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867200B1 (en) | 1998-12-18 | 2005-03-15 | Axys Pharmaceuticals, Inc. | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors |
| MXPA05013922A (es) | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| WO2006113458A1 (en) * | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
| AU2007234399A1 (en) | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| DE602007012133D1 (de) | 2006-12-01 | 2011-03-03 | Andrew Burritt | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| US8785489B2 (en) | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
| JP2012517471A (ja) | 2009-02-11 | 2012-08-02 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法 |
| BRPI1012097A2 (pt) | 2009-06-10 | 2016-03-22 | Sunovion Pharmaceuticals Inc | antagonistas e antagonistas inversos de histamina h3 e métodos de uso dos mesmos. |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| TR201809739T4 (tr) | 2009-07-16 | 2018-07-23 | Mallinckrodt Llc | Toll benzeri reseptör 9 antagonistleri olarak (+)-morfinanlar ve bunların terapötik amaçlı kullanımları. |
| US9241991B2 (en) | 2010-10-21 | 2016-01-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritus and related skin conditions |
| ES2620605T3 (es) | 2011-01-12 | 2017-06-29 | Ventirx Pharmaceuticals, Inc. | Benzoazepinas sustituidas como moduladores de receptores tipo Toll |
| WO2012097173A2 (en) | 2011-01-12 | 2012-07-19 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| EP2713736B1 (en) | 2011-06-01 | 2023-08-02 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| EP2713737B1 (en) | 2011-06-01 | 2016-04-20 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| CN103958495B (zh) | 2011-06-09 | 2018-06-22 | 理森制药股份公司 | 作为gpr-119的调节剂的化合物 |
| CA2841252C (en) | 2011-07-13 | 2019-02-26 | Sk Chemicals Co., Ltd. | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
| WO2013052550A2 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| KR102194585B1 (ko) | 2012-05-18 | 2020-12-23 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 카르복실산 화합물 |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| WO2015057659A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| US9643967B2 (en) | 2013-12-13 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors |
| JP2017525711A (ja) | 2014-08-22 | 2017-09-07 | ジャナス バイオセラピューティクス，インク． | 新規なｎ２，ｎ４，ｎ７，６−四置換プテリジン−２，４，７−トリアミンおよび２，４，６，７−四置換プテリジン化合物ならびにその合成方法および使用 |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| WO2017027645A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| TWI751178B (zh) | 2016-06-29 | 2022-01-01 | 美商基澤生命科學公司 | 肽環氧酮免疫蛋白酶體抑制劑的結晶鹽 |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| AU2017289014B2 (en) | 2016-06-29 | 2019-12-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| AU2017307208B2 (en) | 2016-07-30 | 2021-01-21 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
| JP7028861B2 (ja) | 2016-09-09 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | ピリジル置換のインドール化合物 |
| JP7104775B2 (ja) | 2017-08-04 | 2022-07-21 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物 |
| EP3661934B1 (en) | 2017-08-04 | 2022-06-01 | Bristol-Myers Squibb Company | [1,2,4]triazolo[4,3-a]pyridinyl substituted indole compounds |
| EP3710440B1 (en) | 2017-11-14 | 2023-04-05 | Bristol-Myers Squibb Company | Substituted indole compounds |
| SG11202005513TA (en) | 2017-12-15 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole ether compounds |
| HRP20231244T1 (hr) | 2017-12-18 | 2024-02-16 | Bristol-Myers Squibb Company | Spoj 4-azaindola |
| AU2018390820A1 (en) | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | Substituted indole compounds useful as TLR inhibitors |
| AU2018392316B2 (en) | 2017-12-19 | 2022-05-12 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as TLR inhibitors |
| CN111699185B (zh) | 2017-12-19 | 2023-06-27 | 百时美施贵宝公司 | 6-氮杂吲哚化合物 |
| JP7382938B2 (ja) | 2017-12-20 | 2023-11-17 | ブリストル－マイヤーズ スクイブ カンパニー | ジアザインドール化合物 |
| KR102714788B1 (ko) | 2017-12-20 | 2024-10-08 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr 억제제로서 유용한 아미노 인돌 화합물 |
| JP7291707B2 (ja) | 2017-12-20 | 2023-06-15 | ブリストル－マイヤーズ スクイブ カンパニー | アリールおよびヘテロアリール置換されたインドール化合物 |
| JP7597710B2 (ja) | 2018-10-24 | 2024-12-10 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドール二量体の化合物 |
| WO2020086503A1 (en) | 2018-10-24 | 2020-04-30 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
-
2017
- 2017-06-27 US US15/635,055 patent/US10071079B2/en not_active Ceased
- 2017-06-28 MY MYPI2018002975A patent/MY196474A/en unknown
- 2017-06-28 TW TW106121570A patent/TWI636053B/zh active
- 2017-06-28 EA EA201990048A patent/EA037530B1/ru not_active IP Right Cessation
- 2017-06-28 EP EP17737442.8A patent/EP3478682B1/en active Active
- 2017-06-28 WO PCT/US2017/039633 patent/WO2018005586A1/en not_active Ceased
- 2017-06-28 PE PE2018003329A patent/PE20190324A1/es unknown
- 2017-06-28 SG SG11201811590RA patent/SG11201811590RA/en unknown
- 2017-06-28 AR ARP170101788A patent/AR108905A1/es active IP Right Grant
- 2017-06-28 DK DK17737442.8T patent/DK3478682T3/da active
- 2017-06-28 CN CN201780052726.1A patent/CN109641895B/zh active Active
- 2017-06-28 MX MX2018015422A patent/MX376212B/es active IP Right Grant
- 2017-06-28 ES ES17737442T patent/ES2886964T3/es active Active
- 2017-06-28 AU AU2017287902A patent/AU2017287902B2/en active Active
- 2017-06-28 KR KR1020197002353A patent/KR102473482B1/ko active Active
- 2017-06-28 HU HUE17737442A patent/HUE056091T2/hu unknown
- 2017-06-28 PT PT177374428T patent/PT3478682T/pt unknown
- 2017-06-28 RS RS20211090A patent/RS62292B1/sr unknown
- 2017-06-28 SM SM20210513T patent/SMT202100513T1/it unknown
- 2017-06-28 LT LTEPPCT/US2017/039633T patent/LT3478682T/lt unknown
- 2017-06-28 JP JP2018568837A patent/JP6995067B6/ja active Active
- 2017-06-28 UY UY0001037310A patent/UY37310A/es active IP Right Grant
- 2017-06-28 SI SI201730890T patent/SI3478682T1/sl unknown
- 2017-06-28 HR HRP20211261TT patent/HRP20211261T8/hr unknown
- 2017-06-28 PL PL17737442T patent/PL3478682T3/pl unknown
-
2018
- 2018-07-23 US US16/042,116 patent/US10478424B2/en not_active Ceased
- 2018-12-25 IL IL263961A patent/IL263961B/en active IP Right Grant
- 2018-12-27 CL CL2018003821A patent/CL2018003821A1/es unknown
-
2019
- 2019-01-24 CO CONC2019/0000686A patent/CO2019000686A2/es unknown
- 2019-01-28 ZA ZA2019/00571A patent/ZA201900571B/en unknown
- 2019-10-15 US US16/653,297 patent/US10912766B2/en not_active Ceased
-
2020
- 2020-12-07 US US17/113,495 patent/US11672780B2/en active Active
-
2021
- 2021-09-15 CY CY20211100814T patent/CY1124514T1/el unknown
-
2022
- 2022-01-25 US US17/584,147 patent/USRE49931E1/en active Active
- 2022-01-25 US US17/584,139 patent/USRE49880E1/en active Active
- 2022-01-25 US US17/584,155 patent/USRE49893E1/en active Active
-
2023
- 2023-04-26 US US18/307,119 patent/US20230255941A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003821A1 (es) | Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo. | |
| CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
| CO2019011584A2 (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos | |
| CL2018000293A1 (es) | Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa | |
| CL2019001664A1 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| EA202091474A1 (ru) | Замещенные индольные соединения, применимые в качестве ингибиторов tlr | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| SV2016005311A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| CL2017000712A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| EA201990169A1 (ru) | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 | |
| BR112018067775A2 (pt) | inibidores de mcl-1 indol substituído | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
| EA201700042A1 (ru) | Соединения имидазопиридазина | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| MX380677B (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. |